Drugs / LTK63
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00369031 Comparator | Sep 2006 → Nov 2007 | HIV infectious disease | St George's, University of London | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTK63 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00369031 ↗ |
| Known as | Labile Toxin mutant LTK63 | “Labile Toxin mutant LTK63 adjuvant” NCT00369031 ↗ |
| Route | Intranasal | “Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally” NCT00369031 ↗ |